Acute heart failure prevention resident survival guide

Revision as of 21:09, 6 May 2014 by Ayokunle Olubaniyi (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{MS}}; {{AO}} ==Overview== ==Prevention== {{familytree/start}} {{familytree | | | | | A00 | | A00=<div style="float: left; text-align: left; width...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]; Ayokunle Olubaniyi, M.B,B.S [3]

Overview

Prevention

 
 
 
 
Does the patient have stage A or stage B of heart failure according to the ACCF/AHA staging system?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes, the patient has stage A

Therapeutic goals:
❑ Promote healthy lifestyle
❑ Prevent CAD and comorbidities

❑ Prevent LV structural abnormalities
 
Yes, the patient has stage B

Therapeutic goal:

❑ Prevent symptoms of heart failure
 
No, the patient does not belong to any of the stages
No preventive therapy is needed
 
 
 
 
 
 
 
 
 
 

❑ Control HTN and lipid disorders

ACE inhibitors or (ARBs) in patients with vascular disease or DM
Statins

❑ Minimize risk factors

❑ Dietary sodium restriction (2-3 g daily)
Smoking cessation
❑ Alcohol abstinence (≤2 standard drinks per day for men; ≤1 for women)
❑ Encourage exercise/physical activity
 

❑ Administer ACE inhibitors or (ARBs) in patients with:

❑ Prior MI and LVEF ≤40% to prevent heart failure (Class I, level of evidence A)
OR
❑ LVEF ≤40% (Class I, level of evidence A)

❑ Administer beta blockers in patients with:

❑ Prior MI and LVEF ≤ 40% to prevent heart failure (Class I, level of evidence B)
❑ LVEF ≤ 40% to prevent heart failure (Class I, level of evidence C)

Statins

❑ Patients with MI (Class I, level of evidence A)

❑ Implantable cardioverter defibrillator (ICD) to prevent sudden death in:

❑ Asymptomatic ischemic cardiomyopathy (Class IIa, level of evidence B)
❑ ≥ 40 day post-MI
❑ LVEF ≤ 30%
❑ On GDMT
The use of CCBs e.g., verapamil and diltiazem in patients with LVEF ≤ 30%
 
 

References


Template:WikiDoc Sources